BIOLOGICAL CONSEQUENCES OF PROTEIN OXIDATION
BIOLOGICAL CONSEQUENCES OF PROTEIN OXIDATION
批准号:
6101263
负责人:
E B SHACTER
金额:
$0.0万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Reactive oxygen compounds such as O2- and H2O2 are generated under
numerous circumstances in vivo and in vitro. In the presence of
transition metals (e.g., iron, copper), these compounds induce covalent
modifications in cellular and purified macromolecules including proteins,
DNA, and lipids. Oxidants are thought to contribute to the etiology of a
wide array of pathologic conditions including ischemia-reperfusion injury,
atherosclerosis, chronic inflammation, and cancer. The focus of our work
is to elucidate the consequences of exposure of biological substrates to
oxidative stress. In these studies, we examined mechanisms of induction
of cytotoxicity by H2O2 with emphasis on understanding the ramifications
for tumor cell biology.
Most pre-clinical safety studies use animals for the establishment of
expected toxicities. These tests are costly monetarily and in terms of
animal life. We are setting up a battery of in vitro pre-clinical assays
to assess cell killing. The field of cytotoxicity has advanced so rapidly
that methods that were accepted 10 years ago are no longer adequate. For
example, we now know that cells dying by apoptosis exclude vital dyes and
that agents that kill by this mechanism can be mistakenly diagnosed as
non-toxic. The development of valid in vitro models for cytoxicity will
enable us to promote better pre-clinical testing and will enhance our
ability to regulate anti-cancer drugs. Our work shows that the mechanism
through which a drug kills tumor cells will impact its efficacy and side
effects. Cytotoxicity is also relevant for regulating thrombolytic
agents since thrombolysis can lead to reperfusion injury, thought to be
caused by oxygen radicals. Future treatments for infarction may involve
combination therapies that include anti-oxidants. Our work gives the
agency the expertise required to regulate novel therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REGULATION OF INTERLEUKIN-6 (IL-6)
-
批准号:2569002
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
REGULATION OF INTERLEUKIN-6 (IL-6)
-
批准号:5200786
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
REGULATION OF INTERLEUKIN-6 (IL-6)
-
批准号:6101262
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
BIOLOGICAL CONSEQUENCES OF PROTEIN OXIDATION
-
批准号:2569003
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
REGULATION OF INTERLEUKIN-6 (IL-6)
-
批准号:6161322
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
BIOLOGICAL CONSEQUENCES OF PROTEIN OXIDATION
-
批准号:6161323
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
BIOLOGICAL CONSEQUENCES OF PROTEIN OXIDATION
-
批准号:5200787
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
BIOLOGICAL CONSEQUENCES OF PROTEIN OXIDATION
-
批准号:3748230
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--
REGULATION OF INTERLEUKIN-6 (IL-6)
-
批准号:3748229
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:E B SHACTER
-
依托单位:--